Neuropeptide Alterations in Type 2 Diabetes Mellitus: A Meta-Analysis of Circulating Spexin and Galanin Levels.

Endocrinol Diabetes MetabSep 1, 2026
Clinical ResearchEndocrinologyOpen access

Roshan Kumar Mahat, Sushil Yadav, Kahkashan Naaz et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined circulating levels of spexin and galanin in patients with type 2 diabetes mellitus (T2DM) compared to non-diabetic controls. The analysis included 19 studies, revealing significantly lower spexin levels (SMD = -2.37) and higher galanin levels (SMD = 1.35) in T2DM patients, indicating potential biomarkers for metabolic dysregulation.

Key findings

  • Circulating spexin levels were significantly lower in T2DM patients (SMD = -2.37).
  • Patients with diabetic complications had reduced spexin levels compared to those with uncomplicated T2DM (SMD = -1.12).
  • Circulating galanin levels were significantly elevated in T2DM patients (SMD = 1.35).
  • Age was identified as a significant moderator of spexin levels.

Why it matters

Understanding the alterations in neuropeptide levels in T2DM can help clinicians identify potential biomarkers for metabolic dysregulation and diabetic complications, which may inform patient management strategies.

What to keep in mind

The findings should be interpreted with caution due to the very low certainty of the available evidence.

Source

PubMed · PMID 42573161Free full text on PubMed Central

Published in Endocrinol Diabetes Metab. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.